AR050158A1 - Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion - Google Patents

Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion

Info

Publication number
AR050158A1
AR050158A1 ARP050102327A ARP050102327A AR050158A1 AR 050158 A1 AR050158 A1 AR 050158A1 AR P050102327 A ARP050102327 A AR P050102327A AR P050102327 A ARP050102327 A AR P050102327A AR 050158 A1 AR050158 A1 AR 050158A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydrogen
group
unsubstituted
Prior art date
Application number
ARP050102327A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR050158A1 publication Critical patent/AR050158A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un compuesto de pirrolopiridina de formula (1), en donde: X1 es NR12 y X2 y X3 conjuntamente forman un grupo -CR13=CR11- o X3 es NR12 y X2 y X1 conjuntamente forman un grupo -CR13=CR11-; R1 se selecciona entre hidrogeno, alquilo C1-6, cicloalquilo C2-6 y alquilo C1-6 sustituido con halo; R2 es hidrogeno o (CH2)mR3 donde m es 0 o 1; o R1 y R2 junto con el átomo de N al que están unidos forman un anillo heterociclilo de 4 a 8 miembros no aromático opcionalmente sustituido; R3 es un grupo heterociclilo de 4 a 8 miembros no aromático, un grupo cicloalquilo C3-8, alquilo C1-0 lineal o ramificado, un alquenilo C2-10, un cicloalquenilo C3-8, un alquinilo C2-10, un cicloalquinilo C3-8 o un grupo fenilo, pudiendo estar cualquiera de ellos sin sustituir o sustituido, o R5; R4 se selecciona entre hidrogeno, alquilo C1-6, cicloalquilo C3-6, alquilo C1-6 sustituido con halo, COCH3, y SO2Me; R5 es una formula (2), en donde: p es 0, 1 o 2, y X es CH2, O, S, o SO2; R6 es fenilo sin sustituir o sustituido, cicloalquilo C3-6 sin sustituir o sustituido o un anillo heterociclilo de 4 a 8 miembros no aromático sustituido; o R4 y R6 junto con el átomo de N al que están unidos forman un anillo heterociclo de 4 a 8 miembros no aromático opcionalmente sustituido; R7 es OH, alcoxi C1-6, NR8aR8b, NHCOR9, NHSO2R9 o SOqR9; R8a es H o alquilo C1-6; R8b es H o alquilo C1-6; R9 es alquilo C1-6; R10 es hidrogeno, alquilo C1-6 sustituido o sin sustituir o cloro; R11 es hidrogeno o alquilo C1-6; R12 es hidrogeno o alquilo C1-6; R13 es hidrogeno o alquilo C1-6; q es 0, 1 o 2; o un derivado farmacéuticamente aceptable del mismo, donde el compuesto no es (tetrahidro-piran-4-il)-amida del ácido 3-metil-7-morfolin-4-il-1H- pirrolo[2,3-c]piridina-4-carboxílico o (tetrahidro-piran-4-ilmetil)-amida del ácido 3-metil-7-morfolin-4-il-1H-pirrolo[2,3-c]piridina-4-carboxílico. Composicion farmacéutica que lo comprende y uso del compuesto para prepararla. Este compuesto se aplica en el tratamiento de afecciones mediadas por la actividad del receptor de cannabinoides 2, como ser trastorno inmune o inflamatorio, dolor inflamatorio, visceral, de cáncer, neuropático, lumbar, musculoesquelético, postoperatorio, agudo y migrana, artritis reumatoide, esclerosis multiple, osteoartritis u osteoporosis.
ARP050102327A 2004-06-09 2005-06-07 Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion AR050158A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds

Publications (1)

Publication Number Publication Date
AR050158A1 true AR050158A1 (es) 2006-10-04

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102327A AR050158A1 (es) 2004-06-09 2005-06-07 Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion

Country Status (26)

Country Link
US (1) US7589206B2 (es)
EP (1) EP1753764B1 (es)
JP (1) JP2008501758A (es)
KR (1) KR20070034049A (es)
AR (1) AR050158A1 (es)
AT (1) ATE412651T1 (es)
AU (1) AU2005251913A1 (es)
BR (1) BRPI0511874A (es)
CA (1) CA2569887A1 (es)
DE (1) DE602005010698D1 (es)
DK (1) DK1753764T3 (es)
ES (1) ES2317244T3 (es)
HK (1) HK1104175A1 (es)
HR (1) HRP20090034T3 (es)
IL (1) IL179603A0 (es)
MA (1) MA28686B1 (es)
MX (1) MXPA06014471A (es)
NO (1) NO20070067L (es)
PE (1) PE20060430A1 (es)
PL (1) PL1753764T3 (es)
PT (1) PT1753764E (es)
RU (1) RU2006147278A (es)
SI (1) SI1753764T1 (es)
TW (1) TW200611695A (es)
UY (1) UY28945A1 (es)
WO (1) WO2005121140A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
MXPA06014471A (es) 2004-06-09 2007-03-21 Glaxo Group Ltd Derivados de pirrolopiridina.
JP4977465B2 (ja) * 2004-07-28 2012-07-18 武田薬品工業株式会社 ピロロ[2,3−c]ピリジン化合物、その製造方法および用途
AU2005280740B2 (en) 2004-09-03 2011-04-28 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
WO2007017237A1 (en) * 2005-08-09 2007-02-15 Glaxo Group Limited Imidazopyridine derivatives as cannabinoid receptor ligands
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2010113834A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ピリミジン化合物
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
KR101760158B1 (ko) 2010-07-29 2017-07-20 아스텔라스세이야쿠 가부시키가이샤 축환 피리딘 화합물
EP2827846B1 (en) * 2012-03-19 2020-08-12 Sharon Anavi-Goffer Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
HUE040645T2 (hu) 2013-06-26 2019-03-28 Abbvie Inc BTK-inhibitor primer karboxamidok
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
AU2019389025A1 (en) * 2018-11-30 2021-06-17 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (en) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (es) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
CO4340691A1 (es) 1994-02-18 1996-07-30 Boehringer Ingelheim Pharma 2-HETEROARIL-5,11-DIHIDRO-6H-DIPIRIDO(3,2-b:2´, 3´ -e) (1, 4)-DIAZEPINAS .
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ5員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0931872B1 (de) 1998-01-23 2003-04-09 Voith Paper Patent GmbH Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000012084A1 (en) 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
AU3868800A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS
EP1171135A4 (en) 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS
WO2000053180A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2002538206A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物
CA2367116A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
DE60109148T2 (de) 2000-04-28 2006-01-05 Acadia Pharmaceuticals Inc., San Diego Muscarinrezeptoren
PL358877A1 (en) 2000-04-28 2004-08-23 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
AU8482301A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
JP4129391B2 (ja) 2000-09-06 2008-08-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2434068A1 (en) 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
US20030069266A1 (en) 2001-02-02 2003-04-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
CZ20033053A3 (en) 2001-05-14 2004-05-12 Bristol@Myersásquibbápharmaácompany Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003009852A1 (en) 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
EP1438310B1 (en) 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
JP2005527542A (ja) 2002-03-27 2005-09-15 グラクソ グループ リミテッド キノリンおよびアザインドール誘導体およびその5−ht6リガンドとしての使用
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004018434A1 (en) 2002-08-21 2004-03-04 Glaxo Group Limited Pyrimidine compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
TW200418830A (en) 2003-02-14 2004-10-01 Wyeth Corp Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
MXPA06014471A (es) 2004-06-09 2007-03-21 Glaxo Group Ltd Derivados de pirrolopiridina.

Also Published As

Publication number Publication date
PT1753764E (pt) 2009-01-28
CA2569887A1 (en) 2005-12-22
MXPA06014471A (es) 2007-03-21
DE602005010698D1 (de) 2008-12-11
SI1753764T1 (sl) 2009-02-28
US7589206B2 (en) 2009-09-15
WO2005121140A1 (en) 2005-12-22
DK1753764T3 (da) 2009-02-16
EP1753764B1 (en) 2008-10-29
KR20070034049A (ko) 2007-03-27
NO20070067L (no) 2007-02-09
HK1104175A1 (en) 2008-01-04
PE20060430A1 (es) 2006-05-25
TW200611695A (en) 2006-04-16
ES2317244T3 (es) 2009-04-16
PL1753764T3 (pl) 2009-04-30
RU2006147278A (ru) 2008-07-20
IL179603A0 (en) 2007-05-15
UY28945A1 (es) 2006-01-31
ATE412651T1 (de) 2008-11-15
MA28686B1 (fr) 2007-06-01
BRPI0511874A (pt) 2008-01-15
HRP20090034T3 (en) 2009-03-31
JP2008501758A (ja) 2008-01-24
US20070219229A1 (en) 2007-09-20
AU2005251913A1 (en) 2005-12-22
EP1753764A1 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
AR050158A1 (es) Compuesto derivado de pirrolopiridina, composicion farmaceutica que lo comprende y su uso para fabricar dicha composicion
AR041016A1 (es) Compuesto de pirimidina, composicion farmaceutica que lo comprende y uso del mismo para preparar dicha composicion
AR065354A1 (es) Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4.
MXPA05010874A (es) Compuestos n-heterociclicos condensados y su uso como antagonistas del receptor del factor liberador de corticotropina.
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
MX2008000115A (es) Derivados de piperidina utiles como antagonistas de histamina h3.
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR071285A1 (es) Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos.
HRP20070307T3 (en) Derivatives of n-[ phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[ (azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
PE20140146A1 (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EA201070235A1 (ru) Новые производные 6-триазолпиридинсульфанил-бензотиазола и -бензимидазола, способ их получения, применение их в качестве лекарственных средств, фармацевтические композиции и новое применение, а именно в качестве ингибиторов met
RS54288B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
BRPI0414592A (pt) antagonistas de receptores de trombina
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PE20200664A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
PE20080205A1 (es) DERIVADOS DE PIRAZOLOPIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSIN QUINASA Tie2
SE0403171D0 (sv) New compounds
WO2008099072A3 (fr) Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister

Legal Events

Date Code Title Description
FB Suspension of granting procedure